Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Advances in Therapy|July 4, 2019
Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 20, 2005
Diagnostic value of quantitative hepatic copper determination in patients with Wilson's DiseasePeter Ferenci, Petra Steindl-Munda, Wolfgang Vogel, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Advances in Therapy|March 6, 2020
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2003
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapyPetra Steindl-Munda, Peter Ferenci, Harald Brunner, et al.
British Journal of Clinical Pharmacology|January 19, 2018
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medicationsFiona Marra, Christoph Höner Zu Siederdissen, Saye Khoo, et al.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 7, 2014
Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 studyDouglas Dieterich, Jürgen Kurt Rockstroh, Chloe Orkin, et al.
The Lancet. Infectious Diseases|December 9, 2014
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trialK Rajender Reddy, Stefan Zeuzem, Fabien Zoulim, et al.
BMC Infectious Diseases|June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studyEdward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
Pageof 3